» Articles » PMID: 26274375

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Overview
Journal J Vis Exp
Date 2015 Aug 15
PMID 26274375
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

In this work we describe a novel approach that combines ex vivo drug sensitivity assays and digital image analysis to estimate chemosensitivity and heterogeneity of patient-derived multiple myeloma (MM) cells. This approach consists in seeding primary MM cells freshly extracted from bone marrow aspirates into microfluidic chambers implemented in multi-well plates, each consisting of a reconstruction of the bone marrow microenvironment, including extracellular matrix (collagen or basement membrane matrix) and stroma (patient-derived mesenchymal stem cells) or human-derived endothelial cells (HUVECs). The chambers are drugged with different agents and concentrations, and are imaged sequentially for 96 hr through bright field microscopy, in a motorized microscope equipped with a digital camera. Digital image analysis software detects live and dead cells from presence or absence of membrane motion, and generates curves of change in viability as a function of drug concentration and exposure time. We use a computational model to determine the parameters of chemosensitivity of the tumor population to each drug, as well as the number of sub-populations present as a measure of tumor heterogeneity. These patient-tailored models can then be used to simulate therapeutic regimens and estimate clinical response.

Citing Articles

The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma.

Sudalagunta P, Canevarolo R, Meads M, Silva M, Zhao X, Cubitt C Cancer Res. 2024; 85(2):378-398.

PMID: 39476082 PMC: 11733535. DOI: 10.1158/0008-5472.CAN-24-0886.


Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3-dependent mechanism in vitro and in vivo.

Li L, Hu X, Nkwocha J, Kmieciak M, Meads M, Shain K Br J Haematol. 2024; 205(6):2338-2348.

PMID: 39379134 PMC: 11650795. DOI: 10.1111/bjh.19796.


Utilizing 3D Models to Unravel the Dynamics of Myeloma Plasma Cells' Escape from the Bone Marrow Microenvironment.

Verbruggen S, Freeman C, Freeman F Cancers (Basel). 2024; 16(5).

PMID: 38473251 PMC: 10931336. DOI: 10.3390/cancers16050889.


CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma.

Burger K, Fernandez M, Meads M, Sudalagunta P, Oliveira P, Canevarolo R Cancer Res. 2023; 83(23):3901-3919.

PMID: 37702657 PMC: 10690099. DOI: 10.1158/0008-5472.CAN-22-2350.


Glutathione levels are associated with methotrexate resistance in acute lymphoblastic leukemia cell lines.

Canevarolo R, Pereira de Souza Melo C, Cury N, Artico L, Correa J, Tonhasca Lau Y Front Oncol. 2022; 12:1032336.

PMID: 36531023 PMC: 9751399. DOI: 10.3389/fonc.2022.1032336.


References
1.
Ramasamy K, Khatun H, Macpherson L, Caley M, Sturge J, Mufti G . Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells. Br J Haematol. 2012; 157(5):564-79. DOI: 10.1111/j.1365-2141.2012.09103.x. View

2.
McMillin D, Delmore J, Weisberg E, Negri J, Geer D, Klippel S . Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010; 16(4):483-9. PMC: 3786785. DOI: 10.1038/nm.2112. View

3.
Khin Z, Ribeiro M, Jacobson T, Hazlehurst L, Perez L, Baz R . A preclinical assay for chemosensitivity in multiple myeloma. Cancer Res. 2013; 74(1):56-67. PMC: 3915502. DOI: 10.1158/0008-5472.CAN-13-2397. View

4.
Suggitt M, Bibby M . 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res. 2005; 11(3):971-81. View

5.
Koh C . Preparation of cells for microscopy using cytospin. Methods Enzymol. 2013; 533:235-40. DOI: 10.1016/B978-0-12-420067-8.00016-7. View